Abbott buys AMO, Gets Double-Digit Growth Segment

The ophthalmic industry has traditionally stood alone, with its own device and pharmaceutical companies selling products marketed to specialists. So the announcement on January 12 that diversified giant Abbott Laboratories would acquire Advanced Medical Optics was initially astonishing, as was the hefty premium that Abbott offered. Perhaps Abbott was willing to pay more than it otherwise would have because of the recent divestiture of its Abbott Spine business. In AMO, Abbott is getting a business that almost can't fail to grow by double digits (despite recent economic stresses on the laser vision correction market) because of the demographics of the ophthalmology industry and improving margins on products like intraocular lenses, which serve the burgeoning elderly cataract patient population.

The ophthalmic industry has traditionally stood alone, with its own device and pharmaceutical companies selling products marketed to specialists. So the announcement on January 12 that diversified giant Abbott Laboratories Inc. would acquire Abbott Medical Optics Inc. (AMO) was initially astonishing, as was the hefty premium that Abbott offered. [See Deal] Abbott will pay $22 per share in cash for AMO’s 62 million outstanding shares, a 149% premium over the ophthalmology company’s January 9th closing price of $8.85. Inclusive of AMO net debt, the total value of the transaction is about $2.8 billion, which is more than twice the $1.09 billion in sales revenues that AMO posted in 2007.

Perhaps Abbott was willing to pay more than it otherwise would have because of the recent divestiture of its

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.